Shanghai-based Fosun Pharma has cancelled the proposed acquisition of a 60% stake in OncoCare Cancer Centre, one of the largest private oncology practices in Singapore, according to its filing with the stock exchange.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
